Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial

NCT07492160 is registered in ClinicalTrials.gov with Jefferson Drapkin as lead sponsor.

NCT NCT07492160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07492160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial
Lead sponsor
Jefferson Drapkin
Phase
Phase 2
Overall status
Recruiting
Start date
March 16, 2026
Completion date
April 30, 2028
Enrollment
348 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abortion, pregnancy